Robert E. Reiter, MD, summarizes the impact advanced imaging techniques have had on staging and managing prostate cancer in the past few years. He discusses state-of-the-art molecular imaging, particularly focusing on prostate-specific membrane antigen (PSMA) targeted imaging.Read More
Robert E. Reiter, MD
Geffen School of Medicine at UCLA
Los Angeles, CA
Robert E. Reiter, MD, is the Bing Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at UCLA. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a 12 million dollar research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. Dr. Reiter’s clinical interests include robotic surgical management of prostate cancer, as well as the use of both MRI and molecular imaging tools to manage this disease. His research is focused on the development of novel antibodies for both treatment and imaging of prostate cancer, as well as on the role of epithelial to mesenchymal transition in castration and treatment resistance. Dr. Reiter completed his undergraduate studies at Yale University and medicine at Stanford University Medical School.
Articles by Robert E. Reiter, MD
Posted by Robert E. Reiter, MD | Mar 2018
Robert Reiter, MD, discusses the uses of MRI in prostate cancer management, especially its ability to predict biochemical recurrence (BCR). He also explains the difference between mapping and targeted biopsies, and how MRI suspicion score and tumor volume are associated with grade, stage, and recurrence of disease.Read More